Molecular Insights Into Post-Cardiac Arrest Brain Injury Via CSF Multi-Omics

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorChungnam National University Hospital

About this trial

The goal of this study is to uncover the molecular mechanisms responsible for secondary brain injury in patients with post-cardiac arrest syndrome by analyzing cerebrospinal fluid (CSF) using multi-omics techniques.

The main question this study aims to answer is:

Which genome-, transcriptome-, proteome-, and metabolome-level changes in CSF are associated with secondary brain injury after cardiac arrest?

To address this question, CSF samples collected from post-cardiac arrest patients will undergo multi-omics analyses. Identified molecular pathways will be used to screen existing drug databases and generate new therapeutic candidates through computational modeling and compound synthesis. These findings will provide the scientific foundation needed to design and implement future preclinical experiments using cardiac arrest animal models.

Eligibility criteria

Qualifiers

Patients receiving post-resuscitation care after out-of-hospital cardiac arrest for secondary brain injury treatment.

Uncontrolled diabetes.Coagulation disorders.

Thrombocytopenia (platelet count $< 100,000).

A history of cirrhosis diagnosis.

Disqualifiers

Cerebral Edema: Patients with evidence of cerebral edema on a brain computed tomography (CT) scan performed immediately after spontaneous circulation recovery.

Patients who underwent extracorporeal membrane oxygenation (ECMO).

Patients who could not maintain integrated therapy for more than 24 hours after cardiac arrest.

Patients with a history of acute or chronic brain disease.

Trial design

Treatments tested in this trial

  • Not listed

Trial groups

60 Participants
are grouped into 2 trial groups